TMCnet News

Research and Markets: Hemophilia B Therapeutics Pipeline Report H2 2015 - 19 Companies & 27 Drug Profiles
[December 15, 2015]

Research and Markets: Hemophilia B Therapeutics Pipeline Report H2 2015 - 19 Companies & 27 Drug Profiles


Research and Markets (http://www.researchandmarkets.com/research/8ddmdv/hemophilia_b) has announced the addition of the "Hemophilia B - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Hemophilia B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia B and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.



Companies Involved in Therapeutics Development

  • Alnylam Pharmaceuticals, Inc.
  • Amarna Therapeutics B.V.
  • AstraZeneca Plc
  • Baxalta Incorporated
  • Bayer AG
  • Biogen, Inc.
  • Catalyst Biosciences, Inc.
  • CSL Limited
  • Dimension Therapeutics, Inc.
  • Emergent BioSolutions Inc.
  • Novo Nordisk A/S
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Pharming Group N.V.
  • RegenxBio Inc.
  • rEVO Biologics, Inc.
  • Sangamo BioSciences, Inc.
  • Spark Therapeutics, Inc.
  • uniQure N.V.

Drug Profiles


  • albutrepenonacog alfa
  • ALN-AT3
  • AMT (News - Alert)-060
  • AZ-10047130
  • BAX-335
  • BAY-1093884
  • CB-2679d
  • CB-813d
  • Cell Therapy for Hemophilia B
  • coagulation factor IX (recombinant)
  • coagulation factor IX-Fc (recombinant), Fc fusion protein
  • coagulation factor VIIa (recombinant)
  • concizumab
  • CSL-689
  • DTX-101
  • Gene Therapy for Hemophilia B
  • Gene Therapy to Activate Factor IX for Hemophilia B
  • Gene Therapy to Activate Factor IX for Hemophilia B
  • LR-769
  • MOD-5014
  • MOD-9017
  • nonacog beta pegol
  • PF-06741086
  • SB-FIX
  • SPK-FIX
  • SVF-VIIa

For more information visit http://www.researchandmarkets.com/research/8ddmdv/hemophilia_b


[ Back To TMCnet.com's Homepage ]